Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
Two decades ago, cardiology underwent a revolution when interventionalists began using smaller tools to repair heart damage that once required an open incision. Interventional cardiology didn’t emerge smoothly into mainstream health care as cardiologists fought the push, but the impact on costs and efficacy of treating damaged hearts or vessels can’t be refuted.
Ophthalmology has seen a similar change, at least in the normally sleepy field of glaucoma, which is actually a group...
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
